FLT3 and acute myeloid leukemia: In AML patients 60 years old or older, the presence of NPM1 mutation, co-occurring with mutations in chromatin remodeling, cohesion complex, methylation-related, spliceosome, and/or RAS pathway genes, FLT3-TKD, without FLT3-ITD, identifies a subset of patients with favorable response to chemotherapy; patients with NPM1 mutations and SF1 mutations displayed a favorable overall survival [65].